New anti-angiogenesis agents: Review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

Angiogenesis

Volumn 1, Issue 1, 1997, Pages 23-35

  Masiero, Laura ^a   Figg, William D ^a   Kohn, Elise C ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MSC1500 Bldg 10 ^*  (United States)

Author keywords

Anti angiogenesis; Carboxyamido triazole; Clinical experience; Interleukin 12; Thalidomide; TNP 470

Indexed keywords

EID: 0002581222     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018301031580     Document Type: Review

References (83)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267, 10931.
2. Folkman J, Hochberg M, Knighton D. Self-regulation of growth in three dimensions: the role of surface area limitations. In: Clarkson B, Baserga R (eds), Control of Proliferation in Animal Cells. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 1974: 833-842.
3. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55, 1856-1862.
4. Gottlieb AI, Langille BL, Wong MKK, Kim DW. Biology of disease: structure and function of the endothelial cytoskeleton. Lab Invest 1991 65, 123-137.
5. Gimbrone M, Leapmans S, Cotrans R, Folkman J. Tumor dormancy in vitro by prevention of neovascularization. J Exp Med 1972; 136, 261-276.
6. Brem SS, Jensen HM, Gullino PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978; 41, 239-244.
7. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments]. Nat Med 1995; 1, 149-153.
8. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de nova tumor growth. Proc Natl Acad Sci USA 1996; 93, 2002-2007.
9. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and would healing. N Engl J Med 315, 1650-1659.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86, 356-364.
11. Good DJ, Polverinin PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87, 6624-6628.
12. Folkman J. Clinical applications of research on angiogenesis. New Eng J Med 1996; 333, 1757-1763.
13. Kohn EC, Felder CC, Jacobs W, et al. Structure function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 1994; 54, 935-942.
14. Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 1992; 52, 3208-3212.
15. Kohn EC, Alessandro R, Spoonster J, Wersto R, Liotta LA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 1995; 92, 1307-1311.
16. McBride W. Thalidomide and congenital abnormalities. Lancet 1968; ii: 1358.
17. D' Amato R, Loughnan M, Flynn E, Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci. USA 1994; 91, 4082-4085.
18. Ingber D, Fujita T, Kishimoto S, Sudo K. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555.
19. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69, 212-216.
20. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153, 1697-1706.
21. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178, 1223-1230.
22. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87, 581-586.
23. Cole K, Kohn EC. Calcium-mediated signal transduction: biology, biochemistry, and therapy. Cancer Met Rev 1994; 13, 33-41.
24. Brown AM, Birnbaumer L. Ionic channels and their regulation by G protein subunits. Annu Rev Physiol 1990; 52, 197-213.
25. Felder CC, Singer-Lahat D. Voltage-independent calcium channels. Regulation by receptors and intracellular calcium stores. Biochem Pharmacol 1994; 48, 1997-2004.
26. Berridge MJ. Inositol trisphosphate and calcium signaling. Ann NY Acad Sci 1995; 766, 31-43.
27. Baran I. Calcium and cell cycle progression: possible effects of external perturbations on cell proliferation. Biophys J 1996; 70, 1198-1213.
28. Yoshinaga IG, Dekker SK, Mihm MC, Byers HR. Differential effect of magnesium and calcium on integrin-melanoma cell migration on type IV collagen and fibronectin. Melanoma Res 1994; 4, 371-378.
29. Preston GA, Barrett JC, Biermann JA, Murphy E. Effects of alterations in calcium homeostasis on apoptosis during neoplastic progression. Cancer Res 1997; 57, 537-542.
30. Rodland KD, Wersto RP, Hobson S, Kohn EC. Thapsigargin-induced gene expression in non-excitable cells is dependent on calcium influx. Mol Endocrinol 1997; 11, 281-291.
31. Felder CC, Ma AL, Liotta LA, Kohn EC. The anti-proliferative and antimetastatic compound L651582, inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 1991; 257, 967-971.
32. Alessandro R, Masiero L, Liotta LA, Kohn EC. The role of calcium in the regulation of invasion and angiogenesis. In Vivo 1996; 10, 153-160.
33. Kohn EC, Reed E, Sarosy G, et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996; 56, 569-573.
34. Kohn EC, Figg WD, Sarosy GA, et al. Phase I trial of micronized formulation CAI in patients with refractory solid tumors: pharmacokinetics, clinical outcome and comparison of formulations. J Clin Oncol 1997; 15, 1985-1993.
35. Pearson JMH, Vedagiri M. Treatment of moderately severe erythema nodosum leprosum with thalidomide - a double-blind controlled trial. Leprosy Rev 1969; 40, 111-116.
36. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336, 1487-1493.
37. Vogelsang GB, Farmer ER, Hess AD. Thalidomide for the treatment of chronic graft-versus host disease. N Engl J Med 1992; 326, 1055-1058.
38. Lenz W. Thalidomide and congenital abnormalities: Lancet 1962; i: 45-46.
39. Dixon SC, Bauer KS, Zalles A, Lush RM, Figg WD. Thalidomide effects on angiogenesis and PSA expression. Proc Am Ass Cancer Res 1997; 38, 428a.
40. Gordon GB, Spielberg SP, Blake DA, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 1981; 78, 2545-2548.
41. Figg WD, Bergan R, Brawley O, et al. Randomized Phase II study of thalidomide in androgen independent prostate cancer. Proc Am Soc Clin Oncol 1997; 16: 333a.
42. Fine HA, Loeffler JS, Kyritsis A, et al. A phase I trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high grade gliomas. Proc Am Soc Clin Oncol 1997; 16, 385a.
43. Sheskin J, Yarr I. Motor-conduction velocity of cubital nerves in patients with leprosy reactions. Summary of a 13-year observation series during thalidomide therapy. Hautarzt 1979; 30, 376-379.
44. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989; 16, 158-163.
45. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108, 461-466.
46. Ochonisky S, Verroust J, Bastuju-Garin S, Cherardi R, Revus J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130, 66-69.
47. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120, 338-341.
48. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neuro Neurosurg Psychiat 1968; 31, 543-551.
49. Wulff CH, Hoyer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112, 457-480.
50. Hess CW, Hunziker R, Kupfer A, Ludin HP. Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986; 233, 83-89.
51. Locker D, Superstine E, Sulman FG. The metabolism of the push and pull principle. Endocrine effects of thalidomide and its analogues. Arch Int pharmacodyn Ther 1971; 194, 39-55.
52. Bakay B, Nyhan WL. Binding of thalidomide by macromolecules in the fetal and maternal rat. J Pharmacol Exp Ther 1969; 161, 348-360.
53. Chen TL, Vogelsang GB, Petty BG. et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Disp 1989; 17, 402-405.
54. Hanson FR, Eble TE. An antiphage agent isolated from Aspergillus sp. J Bacteriol 1949; 58, 527-529.
55. Killough JH, Magill GB, Smith RC. The treatment of amebiasis with fumagillin. Science 1952; 115, 71-72.
56. DiPaolo JA, Tarbell DS, Moore GE. Studies on the carcinolytic activity of fumagillin and some derivatives. Antibiotics Annual 1958-1959; 541-546.
57. Hori A, Ikeyama S, Sudo K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun 1994; 204, 1067-1073.
58. Tanaka Y, Kawamata H, Fujimoto K, Oyasu R. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J Urol 1997; 157, 683-688.
59. Yamaoka M, Yamamoto T, Ikeyama A, Sudo K, Fumita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993; 53, 5233-5236.
60. Yanase T, Tamura M, Fujita K, Kodoma S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53, 2566-2570.
61. Yazaki T, Takamiya Y, Costello PC, et al. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol 1995; 23, 23-29.
62. Taki T, Ohnishi T, Arita N, et al. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J Neurooncol 1994; 19, 251-258.
63. Pluda JM, Lietzau J, Wyvill KA. Phase-I trial administering TNP-470 (AGM-1470) to patients with HIV-associated Kaposi's syndrome (abstr). In: Proc 1st Natl Conf on Human Retroviruses and Related Infections 1993; 1, 61.
64. Pluda JM, Wyvill K, Figg WD. A phase-I study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients with HIV-associated Kaposi's sarcoma (abstr). Proc Am Soc Clin Oncol 1994; 13: 8.
65. Dezube BJ, Von Roenn JH, Holden-Wiltse J et al. Fumagillin analog (TNP-470) in the treatment of Kaposi's sarcoma - a phase-I AIDS clinical trial group study. In: Proc Natl AIDS Malignancy Conference 1997; A35.
66. Cretton-Scott E, Placidi L, McClure H, Anderson DC, Sommadossi JP. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl)fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother Pharmacol 1996; 38, 117-122.
67. Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, Sommadossi JP. Diposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) in human hepatocytes and tissue microsomes. Cancer Res 1995; 55, 3036-3042.
68. Placidi L, Scott EC, de Sousa G, Rahmani R, Placidi M, Sommadossi JP. Interspecies variability of TNP-470 metabolism, using primary monkey, rat, and dog hepatocytes. Drug Metab Disp 1997; 25, 94-99.
69. Figg WD, Pluda JM, Lush RM, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997; 17, 91-97.
70. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170, 827-845.
71. Gately MK, Desai B, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12. J Immunol 1991; 147, 874.
72. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J Exp Med 1991; 173, 869.
73. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996; 4, 471-481.
74. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces T helper 1-directed anti-tumor response. J Immunol 1997; 158, 3359-3365.
75. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1994; 326, 1456-1463.
76. Brunda MJ, Sulich V, Bellantoni D. The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location. Int J Cancer 1987; 40, 807-810.
77. Rutenfranz I, Kirchner H. Pharmacokinetics of recombinant murine interferon-gamma in mice. J Interferon Res 1988; 8, 573-580.
78. Luster A, Unkeless J, Ravbetch J. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315, 672-676.
79. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182, 155-162.
80. Bukowski RM, Olencki T, Sandstrom K, et al. Phase I trial of subcutaneous interleukin-12 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1997; 16: 108a.
81. Goey SH, Aulitzky W, Ogilvie A, et al. Recombinant human interleukin-12 in metastatic renal cell cancer patients: a phase I study. Proc Am Soc Clin Oncol 1997; 16: 435a.
82. Lamers C, Gratama J, Ogilvie A, et al. Exogenous IL-12 induces in vivo IL-10 production, followed by downregulation of IL-12 activities. Proc Am Soc Clin Oncol 1997; 16: 435a.
83. Tahara H, Zitvogel L, Storkus WJ, et al. Antitumor effects in patients with melanoma, head and neck and breast cancer in a phase I/II clinical trial of interleukin-12. Proc Am Soc Clin Oncol 1997; 16: 438a.